Prevalence and Risk Factors for Colistin-resistant Acinetobacter baumannii Infection among         Patients in Udon Thani Hospital

Sureerat  Watcharasuwanseree; Chattarin  Kanungbutr

Authors

Sureerat Watcharasuwanseree Department of Internal Medicine, Udon Thani hospital
Chattarin Kanungbutr Department of Internal Medicine, Udon Thani hospital

Keywords:

Colistin-resistant Acinetobacter baumannii, risk factor, infection

Abstract

Colistin-resistant Acinetobacter baumannii is currently the extensive drug-resistant organism causing nosocomial infection. This study aimed to identify the prevalence and risk factors for colistin-resistant A. baumannii infection among patients in Udon Thani hospital. This single-center retrospective study was conducted at Udon Thani Hospital, Thailand, from January 2018 to December 2020. We analyzed 140 patients with non-colistin-resistant A. baumannii (non-CoR-AB) infection and 20 patients with colistin-resistant A. baumannii (CoR-AB) infection. Data analysis using descriptive statistics such as frequency, percentage, mean and standard deviation. Inferential Statistics for between-group comparisons using Fisher's exact test and Student's t-test. Risk Factors for CoR-AB infection were analyzed using univariable logistic regression and multivariable logistic regression, presenting Adjusted Odds Ratio (AOR), and 95% confidence interval (95% CI) at a significant level of p<0.05.

Results: The prevalence of CoR-AB infection was 0.69% (20/2,907). Univariable analysis was performed to evaluate the risk factors for CoR-AB infection. CKD (OR 3.64, 95% CI 1.00-13.18, p = 0.05), Duration of clindamycin (OR 1.18, 95% CI 1.03-1.34, p = 0.02), Duration of ceftazidime (OR 1.12, 95% CI 1.01-1.23, p = 0.03), Duration of mechanical ventilator more than 14 days (OR 3.24, 95% CI 1.24-8.49, p = 0.02), Duration of foley catheterization more than 30 days (OR 3.23, 95% CI 1.15-9.08, p = 0.03), Duration of hospital stay before infection (OR 1.08, 95% CI 1.02-1.14, p = 0.01) were associated with CoR-AB infection. But the two groups showed no significant differences in multivariable analysis.

Conclusion: From January 2018 to December 2020, the prevalence of CoR-AB infection in UTH was 0.69% (20/2,907). This study could not identify significant risk factors for CoR-AB infection. Data about the risk factors of the resistant pathogen is crucial for appropriate standard of care that prevents the infection caused by super bug.

References

Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148-165.

Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY, et al. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect. 2007;13(2):196–198.

Tseng YC, Wang JT, Wu FLL, Chen YC, Chie WC, Chang SC. Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 2007;59(2):181–190.

Xiao D, Wang L, Zhang D, Xiang D, Liu Q, Xing X. Prognosis of patients with Acinetobacter baumannii infection in the intensive care unit: A retrospective analysis. Exp Ther Med 2017;13(4):1630–1633.

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018;18(8):318–327.

Results of antimicrobial resistance surveillance [Internet]. 2021 [cited 2023 Feb 26]. Available from: http:narst.dmsc.moph.go.th/data/AMR%202000-2021-12M.pdf

Naksena P, Prombhul S, Pelletier M, Ernst R, Tribuddharat, C, Thaipisuttikul. Determination of colistin resistance mechanism of Acinetobacter baumannii isolated in Siriraj Hospital, Thailand. Int J Infect Dis 2012;16:e433–e434.

Thet KT, Lunha K, Srisrattakarn A, Lulitanond A, Tavichakorntrakool R, Kuwatjanakul W, et al. Colistin heteroresistance in carbapenem-resistant Acinetobacter baumannii clinical isolates from a Thai university hospital. World J Microbiol Biotechnol 2020;36(7):102.

Lertsrisatit Y, Santimaleeworagun W, Thunyaharn S, Traipattanakul J. In vitro activity of colistin mono- and combination therapy against colistin-resistant Acinetobacter baumannii, mechanism of resistance, and clinical outcomes of patients infected with colistin-resistant A. baumannii at a Thai university hospital. Infect Drug Resist 2017;10:437–443.

Kidney Disease: Improving Global Outcome (KDIGO) CKD Work group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024;105(4S):S117–S314.

CLSI. Performance standards for antimicrobial susceptibility testing. 28th ed. Wayne(PA): Clinical and Laboratory Standards Institute; 2018. p.42-44.

Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 2012;67:1607-1615.

Hejnar P, Kolar M, Hajek V. Characteristics of Acinetobacter strains (phenotype classification, antibiotic susceptibility and production of beta-lactamases) isolated from hemocultures from the patients at the Teaching Hospital in Olomouc. Acta Univ Palacki Olomuc Fac Med 1999;142:73-77.

Su G, Xu H, Riggi E, He Z, Lu L, Lindholm B, et al. Association of Kidney Function with Infections by Multidrug-Resistant Organisms: An Electronic Medical Record Analysis. Sci Rep 2018;8(1):13372.

Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148–165.

Kiddee A, Assawatheptawee K, Naudom A, Treebupachatsakul P, Wangteeraprasert A, Walsh TR, et al. Risk Factors for Gastrointestinal Colonization and Acquisition of Carbapenem-Resistant Gram-Negative Bacteria among Patients in Intensive Care Units in Thailand. Antimicrob Agents Chemother 2018;62(8):e00341-18.

da Silva MCB, Werlang MHB, Spada Jr V, Wendt GW, Vieira AP, Follador Fac, et al. Risk Factors Associated with Acinetobacter baumannii Infections in Patients in an Intensive Care Unit of a Public Hospital in Paraná. Adv Infect Dis 2022;12:90-105.

Vázquez-López R, Solano-Gálvez SG, Juárez Vignon-Whaley JJ, Abello Vaamonde JA, Padró Alonzo LA, Rivera Reséndiz A, et al. Acinetobacter baumannii Resistance: A Real Challenge for Clinicians. Antibiotics (Basel) 2020;9(4):205.

Smani Y, McConnell MJ, Pachón J. Role of Fibronectin in the Adhesion of Acinetobacter baumannii to Host Cells. PLoS ONE 2012;7(4):e33073.

Klompas M, Branson R, Cawcutt K, Crist M, Eichenwald EC, Greene LR, et al. Strategies to prevent ventilator-associated pneumonia, ventilator-associated events, and nonventilator hospital-acquired pneumonia in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol 2022;43(6):687-713.

Patel PK, Advani SD, Kofman AD, Lo E, Maragakis LL, Pegues DA, et al. Strategies to prevent catheter-associated urinary tract infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol 2023;44(8):1209-1231.

Chaiwarith R, Mahatthanaphak S, Boonchoo M, Supparatipinyo K, Sirisanthana T. Pandrug-resistant Acinetobacter baumannii at Maharaj Nakorn Chiang Mai Hospital. J Infect Dis Antimicrob Agents 2005;22:1-8.